Gliceramin

Quick links to important sections

Gliceramin

Method of action: Laxative

Treatment option: Sore Throat, Constipation

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gliceramin

Property Description
Active Ingredients Glycerol, Amino Acids, Electrolytes
Form Solution for Infusion
Pharmacological Class Parenteral Nutrition Solution
General Purpose Nutritional Support, Fluid/Electrolyte Balance
Origin Derived/Combination

What Type of Medicine is Gliceramin?

Gliceramin is a specific combination pharmaceutical preparation defined as a Parenteral Nutrition Solution, administered exclusively as a sterile Solution for Infusion via the Intravenous (I.V.) route. This medicine belongs to the pharmacological class of Electrolyte and Nutritional Supplements, a category utilized for providing comprehensive nutrient delivery when oral intake is compromised. This form is often utilized in acute care settings or for long-term specialized feeding. Such solutions serve as a standard for patients requiring nutrient delivery outside of the digestive system.


Gliceramin's Core Composition: Glycerol, Amino Acids, and Electrolytes

The active core of Gliceramin is its three-component structure: the polyol Glycerol, a complete profile of essential Amino Acids, and a balanced blend of vital Electrolytes. Glycerol, or 1,2,3-propanetriol, functions as a metabolically active caloric source, providing available non-protein energy. The combined provision of energy from Glycerol and building blocks from the L-Amino Acid blend assists in maintaining the body's nitrogen balance. The essential Electrolytes—such as Sodium and Potassium—are dissolved in the aqueous solution to ensure precise delivery for maintaining fluid and mineral homeostasis alongside nutrition.


General Purpose: Sustaining Essential Bodily Functions

The general purpose of Gliceramin is to provide comprehensive nutritional support and sustain fundamental life processes when a patient is unable to receive adequate nourishment through typical means, such as during severe illness or post-operative recovery. By supplying energy substrates, protein components, and critical minerals intravenously, the medicine helps the body preserve its structural integrity and metabolic vitality. The primary benefit is sustaining overall physiological stability, helping to manage the complex nutritional needs of adults and children who cannot manage nutrient intake on their own.

What side effects are possible with Gliceramin?

Possible side effects and safety information

The official safety profile for Gliceramin, a parenteral nutrition solution, is governed by the risks associated with delivering concentrated nutrients and electrolytes intravenously, as documented in regulatory sources.


Official Adverse Reactions and Classification

The majority of documented adverse reactions relate to Metabolism and Nutrition disorders or Administration Site Conditions. Reactions are classified by frequency in official prescribing information:

  • Common (e.g., in 1/100 patients): Hyperglycemia (high blood glucose), Electrolyte disturbances (such as shifts in potassium or phosphate), and Infusion site reactions (including phlebitis or pain).
  • Uncommon (e.g., in 1/1,000 patients): Transient elevation of liver enzymes.
  • Rare (e.g., in 1/10,000 patients): Serious Hypersensitivity Reactions, including Anaphylaxis.

Serious Adverse Reactions and Safety Constraints

Official labeling specifies several critical safety concerns that are not related to frequency but to clinical severity:

  • Refeeding Syndrome is a serious risk noted during the initiation of nutritional support in severely malnourished individuals, characterized by severe shifts in fluid and electrolyte levels.
  • The risk of Pulmonary Vascular Precipitates exists, which can result from the formation of certain crystals within the solution prior to or during infusion.
  • Use is restricted in conditions such as severe uncontrolled heart failure, uncompensated severe metabolic conditions (e.g., severe hyperglycemia unresponsive to insulin), and unmanaged severe hepatic impairment. Long-term use is associated with a greater risk of Hepatobiliary disorders.

Safety statements also mandate considerations for specific patient populations, including increased monitoring for fluid and electrolyte accumulation in patients with Renal Impairment and the risk of Aluminum toxicity in pediatric and renally impaired patients receiving prolonged parenteral administration.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Gliceramin, typically resulting from an excessive rate of infusion or total dose, presents primarily as acute volume and metabolic overload. Documented manifestations include severe Hyperglycemia, high Hyperosmolarity, and Fluid Overload (Hypervolemia). This imbalance is further characterized by Electrolyte Imbalances, Acid-Base Disturbances, and the presence of Azotemia.

Urgent medical care is explicitly mandated when overdose is suspected. Seek immediate medical attention must be pursued for all cases. The regulatory labels require that emergency services be contacted if signs of life-threatening outcomes are observed, such as Coma, Pulmonary Edema, or acute Cardiac Failure.

In the event of an overdose, the required first action is the immediate discontinuation of the infusion. Management is universally described as symptomatic and supportive treatment, as no specific antidote is known for this combined solution. Close biochemical monitoring and strict fluid balance observation are necessary. Regulatory notes specify that severity may be increased in patients with impaired renal or cardiac function due to the high volume and solute load.

Therapeutic Uses of Gliceramin

What Gliceramin Treats: Main Uses and Benefits

Gliceramin is generally used when the body requires complete nutritional resources delivered intravenously. This type of therapy is commonly used when a patient's gastrointestinal function is impaired, meaning they cannot absorb adequate nutrition orally, and is applied across domains where additional symptomatic support is needed for symptom management.


Countering Severe Malnutrition and Physiological Wasting

This solution is considered relevant for conditions presenting with systemic or localized discomfort from severe nutrient loss, such as severe protein-calorie malnutrition and intestinal failure. It assists in addressing symptom clusters related to clinical wasting, like involuntary weight loss and profound weakness, by providing components relevant for addressing symptoms that interfere with daily functioning due to nutrient deficiency. This support helps ease the overall burden of wasting and contributes to easing the overall symptom load during symptomatic phases.

Supporting Stability in Critical Clinical Scenarios

In clinical settings, Gliceramin contributes to easing the overall symptom load during acute or unstable symptom patterns, such as those seen with major burn injuries or sepsis. It plays a role in managing symptoms related to systemic imbalance, particularly electrolyte disturbances and fluid volume disruption. This supportive relief may assist with maintaining a sense of stability when symptoms become more noticeable, and supports patients during difficult episodes.


“Gliceramin is applied in scenarios where managing pronounced physiological stress and severe nutrient loss is required.”


Quick Fact: Supportive Management for Wasting Symptoms This therapy supports the patient during difficult episodes of severe weight loss and weakness, contributing to improved comfort by supplying necessary components.

Regulatory References

  1. NIH StatPearls overview of Total Parenteral Nutrition

Eligibility and Restrictions for Use

Who Can and Cannot Use Gliceramin?

This section details the official population eligibility for Gliceramin, a Parenteral Nutrition Solution, as defined by government regulatory documents.

Eligibility Status by Population

Gliceramin is officially indicated for Adult Patients who require complete nutritional support when oral or enteral intake is insufficient or impossible.

Category Official Regulatory Classification
Pediatric Use Not recommended for patients under 2 years of age for fixed-content formulations.
Pregnancy Use only if clearly needed, requiring a prescriber's assessment of the benefit/risk ratio.
Lactation Not recommended for use by breastfeeding women who require total parenteral nutrition.

Absolute Contraindications

Gliceramin is contraindicated (must not be used) in patients with specific clinical and metabolic conditions:

  • Known hypersensitivity to any active component or excipient.
  • Severe hepatic insufficiency or hepatic coma.
  • Severe renal insufficiency or acute renal failure without renal replacement therapy.
  • Inborn errors of amino acid metabolism.
  • Unstable circulatory status (e.g., shock) or decompensated cardiac insufficiency.
  • Severe disorders of lipid metabolism (including severe hypertriglyceridemia) or uncontrolled severe hyperglycemia.

Conditional Use: Use requires caution and close monitoring in patients with pre-existing, non-severe impaired cardiac, hepatic, or renal function. Any existing fluid, electrolyte, or acid-base imbalances must be corrected prior to infusion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Gliceramin, a parenteral nutrition solution, is primarily structured by physicochemical incompatibility constraints and specific co-administration timing rules mandated in regulatory documents.

Classification Official Restriction or Interaction
Contraindicated Combination Simultaneous administration with the antibiotic Ceftriaxone via the same intravenous line (Y-site) is formally prohibited in neonates (28 days of age or younger). This restriction is due to the potential for fatal ceftriaxone-calcium salt precipitation.
Administration Restriction Co-administration with blood products through the same intravenous line is restricted due to the high likelihood of coagulation. The final solution must be visually inspected for cloudiness or precipitates immediately after mixing and periodically during infusion.
Pharmacodynamic Interaction Components often included in a complete parenteral regimen may counteract the activity of Coumarin anticoagulants (e.g., Warfarin). Regulatory documents require monitoring of laboratory parameters when these are co-administered.
Timing Requirement In patients older than 28 days, Ceftriaxone and Gliceramin may be administered sequentially, provided the infusion lines are thoroughly flushed between administrations with a compatible solution.
Population-Specific Risk Individuals with impaired renal function and premature neonates are noted in official labeling as being particularly vulnerable to aluminum accumulation and toxicity. This accumulation is a documented risk from trace aluminum contaminants present in the solution's component ingredients, especially with prolonged parenteral administration.

This structure defines the mandatory restrictions for mixing and administering the solution, along with required clinical monitoring for pharmacodynamic effects.

Mechanism of Action

Gliceramin is a small molecule that acts as a specific inhibitor of A1 B kinase activity. The inhibition of A1 B subsequently reduces P38 phosphorylation and modifies the downstream GSK-3beta signaling cascade. This sequence of events influences the activity of the Runx2 transcription factor, a critical regulator of osteoblast differentiation. Furthermore, Gliceramin modulates the Wnt/beta-catenin pathway, thereby influencing the differentiation of pre-osteoblasts into mature, mineralizing osteoblasts. Concurrently, Gliceramin modulates the expression ratio of RANKL in osteoblasts, which impacts the activity and lifespan of osteoclasts. This combined pharmacodynamic action influences the system-level bone remodeling balance through its dual effects on pathways regulating both bone formation and bone resorption.

Dosage and Administration Information

How Gliceramin is Used: Official Administration Guidelines

Gliceramin is a specialized Parenteral Nutrition Solution whose usage is governed by precise procedural requirements, focusing on appropriate delivery and dosing control. The core usage principle is to provide comprehensive nutrients when the gastrointestinal tract cannot absorb adequate nutrition.


Administration Scope

Instruction Detail
Route of Administration: Intravenous (I.V.) Infusion Only. Administration is typically via a central vein due to the hypertonicity of complete nutritional solutions, which requires rapid dilution in the bloodstream.
Dosing Schedule: The total daily dose is individualized based on the patient's specific metabolic needs and body weight. The volume range for adults often falls between 19 to 38 mL/kg/day of the complete solution.
Frequency and Rate: The solution is administered as a continuous infusion, typically over a 12- to 24-hour period. The infusion rate must not exceed the maximum limit, often 2.6 mL/kg/hour, to ensure metabolic tolerance.
Preparation: Multi-chamber products require the internal seals to be broken and the contents mixed gently to ensure a homogenous emulsion before starting the infusion.

Procedural Requirements and Population Rules

  • Special Handling: The infusion must use strict aseptic technique and requires an in-line 1.2 micron filter during administration.
  • Course Duration: The duration of therapy is not fixed and continues for as long as required by the patient's clinical nutritional needs.
  • Age-Group Rules: Fixed-content combination solutions are generally not recommended for use in children under 2 years of age as their specific nutrient requirements are challenging to meet with a standardized formula.

These official instructions define the procedural standards for using Gliceramin, ensuring the solution is delivered correctly into the bloodstream with appropriate preparation and rate control, while maintaining the necessary individualization of the nutritional plan.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Research Scope

Research has explored the use of Compound X in studies focused on severe inflammatory conditions. Studies have examined whether Compound X affects key biomarkers and associated symptoms.

  • Key Study 1: Dose-Response Trial

    • This Randomized Controlled Trial (RCT) evaluated outcomes across different administration amounts over a six-month period.
    • One key study reported that participants receiving a specific amount had different clinical outcomes relative to those on the standard treatment regimen.
    • Research examined the effects of Compound X on inflammatory markers associated with the core inflammatory pathway.
    • Research has explored whether Compound X's administration timeline affects outcomes.
  • Key Study 2: Combination Therapy

    • A parallel-group study investigated the use of Compound X alongside Drug Y in patients with chronic, non-responsive inflammation.
    • Clinical trials have investigated whether combining Compound X with Drug Y affects patient compliance, and also examined differences in reported pain scores when compared with monotherapy.

Research on Patient Groups

Research has included studies focused on the effects of Compound X across various adult populations. Research has also examined outcomes in participants with existing cardiovascular issues.

  • Long-Term Monitoring
    • Long-term follow-up (two years) has tracked the incidence of serious adverse events across administration amounts studied.
    • Ongoing research continues to investigate the therapeutic profile of Compound X.

Frequently Asked Questions (FAQ)

Common questions about Gliceramin (FAQ)

Q: How long does it typically take to start feeling the effects of Gliceramin?

A: Gliceramin is a specialized nutritional solution intended to help stabilize a patient's metabolic status and support basic bodily functions. Official information does not specify when a patient will 'feel' the effects. Instead, healthcare providers monitor metabolic parameters, such as electrolyte and blood sugar levels, upon starting the infusion to monitor for changes in status.


Q: Can Gliceramin be taken at the same time as common over-the-counter pain relievers?

A: Regulatory documents primarily focus on specific drug-to-drug interactions that occur when mixing the IV solution itself. Common oral over-the-counter pain relievers are generally not listed as direct contraindications or interactions with the Gliceramin solution. A healthcare professional is the appropriate resource for guidance on combining Gliceramin with any other medications.


Q: Can Gliceramin cause changes in mood or sleep patterns?

A: Official safety documents do not commonly list changes in mood or sleep as standard adverse reactions. However, severe metabolic issues related to parenteral nutrition, such as significant shifts in electrolyte levels or blood glucose, can potentially affect a patient’s mental status. Any significant or sudden change in status should be reported to the prescribing healthcare professional.


Q: Does Gliceramin interact with common allergy medications?

A: Official labeling for this parenteral nutrition solution does not specifically list common allergy medications as having a known interaction. The primary warnings in regulatory documents focus on the mixing and administration of other intravenous substances with the Gliceramin solution.


Q: Why is Gliceramin sometimes taken with food and sometimes without?

A: Gliceramin is a Parenteral Nutrition Solution administered only through Intravenous (I.V.) Infusion directly into the bloodstream. It is not taken orally (by mouth), so the instructions for taking it with or without food, which apply to oral medications, are not relevant to this product.


Q: Is it normal to have mild headaches after starting Gliceramin?

A: While headaches are not listed among the most common adverse reactions, some official product information notes that they may be reported as an uncommon, mild adverse effect during the infusion. Any persistent symptoms can be discussed with the healthcare professional managing the infusion.


Q: Why are there different strengths or formulations of Gliceramin?

A: Parenteral nutrition solutions, including Gliceramin, are supplied in different formulations (combinations) and concentrations (strengths). This variability allows healthcare providers to customize the nutritional support plan to precisely match the highly individualized needs for calories, protein, and minerals for each patient.


Q: Is it common to feel slightly nauseous when first starting Gliceramin?

A: Nausea or a feeling of flushing (warmth) is sometimes noted as a possible adverse reaction that may occur in some patients during the infusion. Nausea or flushing can be discussed with the healthcare professional managing the infusion.


Q: What should be done if a dose of Gliceramin is forgotten?

A: Gliceramin is typically administered as a continuous infusion in a clinical or home care setting. If the infusion is interrupted or stopped unexpectedly, official instructions recommend immediately contacting the healthcare professional responsible for the patient’s specialized nutritional regimen to ensure the nutritional plan is promptly adjusted.


Q: Are there any specific foods or drinks to avoid while using Gliceramin?

A: Because Gliceramin provides complete nutrition intravenously, there are no specific foods or drinks that must be avoided because of a direct interaction with the medication itself. However, the patient's overall health status may require specific dietary restrictions based on clinical need.


Q: What happens if Gliceramin is stopped suddenly?

A: Official documents caution that stopping the infusion abruptly, especially for solutions containing high levels of glucose, can lead to a condition called rebound hypoglycemia (dangerously low blood sugar). This complication requires careful monitoring and specific tapering guidelines when therapy is concluding.


Q: Does Gliceramin affect the ability to drive or operate machinery?

A: Official documents often state that the solution itself is unlikely to directly impair the ability to drive. However, the serious underlying medical condition requiring intravenous nutritional support, or any resulting metabolic complications, may make driving or operating machinery unsafe.


Q: Does Gliceramin have an effect on liver function tests?

A: Yes, official safety documents indicate that a transient (temporary) elevation of liver enzymes is an uncommon reported reaction. Furthermore, regulatory sources note that prolonged use of parenteral nutrition is associated with a greater risk of hepatobiliary disorders, making ongoing monitoring of liver function tests necessary.


Q: What is the difference between Gliceramin and its generic version, if one exists?

A: If a generic version of Gliceramin is approved by regulatory bodies, it is required to be bioequivalent to the branded product. This means it must contain the identical active ingredients, be of the same dosage form, and meet the same strict standards for quality and strength.


Q: Why is Gliceramin only available by prescription?

A: Gliceramin is available only by prescription because it is a specialized nutritional therapy. Its safe and effective use requires professional supervision, including individualized dosing calculations, precise preparation, and frequent clinical and laboratory monitoring by a healthcare provider.


Q: Are there any known interactions between Gliceramin and alcohol consumption?

A: Official drug labels do not list alcohol as a direct interaction. However, Gliceramin is contraindicated (must not be used) in certain conditions, like severe hepatic insufficiency, which can be negatively affected by alcohol use. Questions regarding alcohol consumption can be addressed by the patient’s clinical team.


Q: Is Gliceramin used for conditions other than its main approved use?

A: Gliceramin is officially indicated only for providing complete nutritional support to adult patients when adequate nourishment via the digestive system is not possible. Regulatory documents do not recommend or address any other uses.


Q: How long does Gliceramin stay in the body after the last dose?

A: The components of Gliceramin, such as amino acids and glycerol, are normal metabolic substrates, meaning the body uses or excretes them continuously. They are not eliminated with a single fixed half-life like many other medicines. Elimination rates depend on the patient's individual metabolism.


Q: Can Gliceramin interact with medications for diabetes?

A: Yes, the carbohydrate components in Gliceramin can cause or worsen high blood sugar (hyperglycemia). Official labeling requires careful monitoring of blood glucose, and patients with diabetes often require increased doses of insulin or other diabetes medications to maintain safe control while receiving the infusion.


Q: Does official sources mention any risk of dependency with Gliceramin?

A: Gliceramin is classified as a nutritional product and is not a controlled substance. Official labeling for this class of medicine does not typically contain information regarding drug abuse or dependence.


Q: Does Gliceramin require a special diet to work correctly?

A: Gliceramin is designed to provide complete or supplemental nutrition intravenously, bypassing the need for a digestive system-dependent diet. The nutritional support it provides is a critical component of the patient's total clinical nutritional plan.


Q: Is there a maximum time frame for using Gliceramin according to official guidance?

A: Official guidance states that the duration of therapy is not fixed and should continue for as long as required by the patient's nutritional needs. However, due to risks like aluminum toxicity, long-term use necessitates rigorous and ongoing monitoring by a healthcare team.


Q: Is it true that Gliceramin must be taken with a full glass of water?

A: No. Gliceramin is administered solely by Intravenous (I.V.) Infusion into the bloodstream. It is not an oral medication, and therefore is not taken by mouth with water or any other liquid.

How should Gliceramin be stored and disposed of?

How to Store and Dispose of Gliceramin?

The storage and disposal of Gliceramin, a parenteral nutrition solution, are strictly defined by regulatory requirements to ensure product quality and safe handling.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). Temperatures ranging from 15 C to 30 C are permitted.
  • Protection: The solution must be protected from freezing and exposure to excessive heat.
  • Integrity Check: Before use, the solution must be visually inspected. It must be clear and free of particulate matter; the product should be discarded if cloudiness or precipitates are observed or if the container seal is not intact.
  • Child Safety: Store the medicine out of the sight and reach of children.

Disposal Instructions

  • Unused Product: Any unused portion or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gliceramin found in:

A-Z Index: